Table of Content

1 Report Overview
1.1 Antidiabetic Biguanides Definition
1.2 Market by Type
1.2.1 Global Antidiabetic Biguanides Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Metformin IR
1.2.3 Metformin SR
1.3 Market Segment by Application
1.3.1 Global Antidiabetic Biguanides Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Antidiabetic Biguanides Sales
2.1 Global Antidiabetic Biguanides Revenue Estimates and Forecasts 2018-2034
2.2 Global Antidiabetic Biguanides Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Antidiabetic Biguanides Revenue by Region
2.3.1 Global Antidiabetic Biguanides Revenue by Region (2018-2024)
2.3.2 Global Antidiabetic Biguanides Revenue by Region (2024-2034)
2.4 Global Antidiabetic Biguanides Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Antidiabetic Biguanides Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Antidiabetic Biguanides Sales Quantity by Region
2.6.1 Global Antidiabetic Biguanides Sales Quantity by Region (2018-2024)
2.6.2 Global Antidiabetic Biguanides Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Antidiabetic Biguanides Sales Quantity by Manufacturers
3.1.1 Global Antidiabetic Biguanides Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Antidiabetic Biguanides Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Antidiabetic Biguanides Sales in 2022
3.2 Global Antidiabetic Biguanides Revenue by Manufacturers
3.2.1 Global Antidiabetic Biguanides Revenue by Manufacturers (2018-2024)
3.2.2 Global Antidiabetic Biguanides Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Antidiabetic Biguanides Revenue in 2022
3.3 Global Antidiabetic Biguanides Sales Price by Manufacturers
3.4 Global Key Players of Antidiabetic Biguanides, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Antidiabetic Biguanides Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Antidiabetic Biguanides, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Antidiabetic Biguanides, Product Offered and Application
3.8 Global Key Manufacturers of Antidiabetic Biguanides, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Antidiabetic Biguanides Sales Quantity by Type
4.1.1 Global Antidiabetic Biguanides Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Antidiabetic Biguanides Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
4.2 Global Antidiabetic Biguanides Revenue by Type
4.2.1 Global Antidiabetic Biguanides Historical Revenue by Type (2018-2024)
4.2.2 Global Antidiabetic Biguanides Forecasted Revenue by Type (2024-2034)
4.2.3 Global Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
4.3 Global Antidiabetic Biguanides Price by Type
4.3.1 Global Antidiabetic Biguanides Price by Type (2018-2024)
4.3.2 Global Antidiabetic Biguanides Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Antidiabetic Biguanides Sales Quantity by Application
5.1.1 Global Antidiabetic Biguanides Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Antidiabetic Biguanides Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
5.2 Global Antidiabetic Biguanides Revenue by Application
5.2.1 Global Antidiabetic Biguanides Historical Revenue by Application (2018-2024)
5.2.2 Global Antidiabetic Biguanides Forecasted Revenue by Application (2024-2034)
5.2.3 Global Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
5.3 Global Antidiabetic Biguanides Price by Application
5.3.1 Global Antidiabetic Biguanides Price by Application (2018-2024)
5.3.2 Global Antidiabetic Biguanides Price Forecast by Application (2024-2034)
6 North America
6.1 North America Antidiabetic Biguanides Sales by Company
6.1.1 North America Antidiabetic Biguanides Revenue by Company (2018-2024)
6.1.2 North America Antidiabetic Biguanides Sales Quantity by Company (2018-2024)
6.2 North America Antidiabetic Biguanides Market Size by Type
6.2.1 North America Antidiabetic Biguanides Sales Quantity by Type (2018-2034)
6.2.2 North America Antidiabetic Biguanides Revenue by Type (2018-2034)
6.3 North America Antidiabetic Biguanides Market Size by Application
6.3.1 North America Antidiabetic Biguanides Sales Quantity by Application (2018-2034)
6.3.2 North America Antidiabetic Biguanides Revenue by Application (2018-2034)
6.4 North America Antidiabetic Biguanides Market Size by Country
6.4.1 North America Antidiabetic Biguanides Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Antidiabetic Biguanides Revenue by Country (2018-2034)
6.4.3 North America Antidiabetic Biguanides Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Antidiabetic Biguanides Sales by Company
7.1.1 Europe Antidiabetic Biguanides Sales Quantity by Company (2018-2024)
7.1.2 Europe Antidiabetic Biguanides Revenue by Company (2018-2024)
7.2 Europe Antidiabetic Biguanides Market Size by Type
7.2.1 Europe Antidiabetic Biguanides Sales Quantity by Type (2018-2034)
7.2.2 Europe Antidiabetic Biguanides Revenue by Type (2018-2034)
7.3 Europe Antidiabetic Biguanides Market Size by Application
7.3.1 Europe Antidiabetic Biguanides Sales Quantity by Application (2018-2034)
7.3.2 Europe Antidiabetic Biguanides Revenue by Application (2018-2034)
7.4 Europe Antidiabetic Biguanides Market Size by Country
7.4.1 Europe Antidiabetic Biguanides Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Antidiabetic Biguanides Revenue by Country (2018-2034)
7.4.3 Europe Antidiabetic Biguanides Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Antidiabetic Biguanides Sales by Company
8.1.1 China Antidiabetic Biguanides Sales Quantity by Company (2018-2024)
8.1.2 China Antidiabetic Biguanides Revenue by Company (2018-2024)
8.2 China Antidiabetic Biguanides Market Size by Type
8.2.1 China Antidiabetic Biguanides Sales Quantity by Type (2018-2034)
8.2.2 China Antidiabetic Biguanides Revenue by Type (2018-2034)
8.3 China Antidiabetic Biguanides Market Size by Application
8.3.1 China Antidiabetic Biguanides Sales Quantity by Application (2018-2034)
8.3.2 China Antidiabetic Biguanides Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Antidiabetic Biguanides Sales by Company
9.1.1 APAC Antidiabetic Biguanides Sales Quantity by Company (2018-2024)
9.1.2 APAC Antidiabetic Biguanides Revenue by Company (2018-2024)
9.2 APAC Antidiabetic Biguanides Market Size by Type
9.2.1 APAC Antidiabetic Biguanides Sales Quantity by Type (2018-2034)
9.2.2 APAC Antidiabetic Biguanides Revenue by Type (2018-2034)
9.3 APAC Antidiabetic Biguanides Market Size by Application
9.3.1 APAC Antidiabetic Biguanides Sales Quantity by Application (2018-2034)
9.3.2 APAC Antidiabetic Biguanides Revenue by Application (2018-2034)
9.4 APAC Antidiabetic Biguanides Market Size by Region
9.4.1 APAC Antidiabetic Biguanides Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Antidiabetic Biguanides Revenue by Region (2018-2034)
9.4.3 APAC Antidiabetic Biguanides Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Antidiabetic Biguanides Sales by Company
10.1.1 Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Antidiabetic Biguanides Market Size by Type
10.2.1 Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Antidiabetic Biguanides Market Size by Application
10.3.1 Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Antidiabetic Biguanides Market Size by Country
10.4.1 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Pfizer
11.1.1 Pfizer Company Information
11.1.2 Pfizer Overview
11.1.3 Pfizer Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Pfizer Antidiabetic Biguanides Products and Services
11.1.5 Pfizer Antidiabetic Biguanides SWOT Analysis
11.1.6 Pfizer Recent Developments
11.2 AstraZeneca
11.2.1 AstraZeneca Company Information
11.2.2 AstraZeneca Overview
11.2.3 AstraZeneca Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 AstraZeneca Antidiabetic Biguanides Products and Services
11.2.5 AstraZeneca Antidiabetic Biguanides SWOT Analysis
11.2.6 AstraZeneca Recent Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Information
11.3.2 GlaxoSmithKline Overview
11.3.3 GlaxoSmithKline Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 GlaxoSmithKline Antidiabetic Biguanides Products and Services
11.3.5 GlaxoSmithKline Antidiabetic Biguanides SWOT Analysis
11.3.6 GlaxoSmithKline Recent Developments
11.4 Merck & Co
11.4.1 Merck & Co Company Information
11.4.2 Merck & Co Overview
11.4.3 Merck & Co Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Merck & Co Antidiabetic Biguanides Products and Services
11.4.5 Merck & Co Antidiabetic Biguanides SWOT Analysis
11.4.6 Merck & Co Recent Developments
11.5 Eli Lilly
11.5.1 Eli Lilly Company Information
11.5.2 Eli Lilly Overview
11.5.3 Eli Lilly Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Eli Lilly Antidiabetic Biguanides Products and Services
11.5.5 Eli Lilly Antidiabetic Biguanides SWOT Analysis
11.5.6 Eli Lilly Recent Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Overview
11.6.3 Sanofi Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Sanofi Antidiabetic Biguanides Products and Services
11.6.5 Sanofi Antidiabetic Biguanides SWOT Analysis
11.6.6 Sanofi Recent Developments
11.7 Takeda Pharmaceuticals
11.7.1 Takeda Pharmaceuticals Company Information
11.7.2 Takeda Pharmaceuticals Overview
11.7.3 Takeda Pharmaceuticals Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Takeda Pharmaceuticals Antidiabetic Biguanides Products and Services
11.7.5 Takeda Pharmaceuticals Antidiabetic Biguanides SWOT Analysis
11.7.6 Takeda Pharmaceuticals Recent Developments
11.8 Novo Nordisk
11.8.1 Novo Nordisk Company Information
11.8.2 Novo Nordisk Overview
11.8.3 Novo Nordisk Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Novo Nordisk Antidiabetic Biguanides Products and Services
11.8.5 Novo Nordisk Antidiabetic Biguanides SWOT Analysis
11.8.6 Novo Nordisk Recent Developments
11.9 Servier Laboratories
11.9.1 Servier Laboratories Company Information
11.9.2 Servier Laboratories Overview
11.9.3 Servier Laboratories Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Servier Laboratories Antidiabetic Biguanides Products and Services
11.9.5 Servier Laboratories Antidiabetic Biguanides SWOT Analysis
11.9.6 Servier Laboratories Recent Developments
11.10 Boehringer Ingelheim
11.10.1 Boehringer Ingelheim Company Information
11.10.2 Boehringer Ingelheim Overview
11.10.3 Boehringer Ingelheim Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Boehringer Ingelheim Antidiabetic Biguanides Products and Services
11.10.5 Boehringer Ingelheim Antidiabetic Biguanides SWOT Analysis
11.10.6 Boehringer Ingelheim Recent Developments
11.11 Bristol-Myers Squibb
11.11.1 Bristol-Myers Squibb Company Information
11.11.2 Bristol-Myers Squibb Overview
11.11.3 Bristol-Myers Squibb Antidiabetic Biguanides Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Bristol-Myers Squibb Antidiabetic Biguanides Products and Services
11.11.5 Bristol-Myers Squibb Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Antidiabetic Biguanides Value Chain Analysis
12.2 Antidiabetic Biguanides Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Antidiabetic Biguanides Production Mode & Process
12.4 Antidiabetic Biguanides Sales and Marketing
12.4.1 Antidiabetic Biguanides Sales Channels
12.4.2 Antidiabetic Biguanides Distributors
12.5 Antidiabetic Biguanides Customers
13 Market Dynamics
13.1 Antidiabetic Biguanides Industry Trends
13.2 Antidiabetic Biguanides Market Drivers
13.3 Antidiabetic Biguanides Market Challenges
13.4 Antidiabetic Biguanides Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Metformin IR
Table 3. Major Manufacturers of Metformin SR
Table 4. Global Antidiabetic Biguanides Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Antidiabetic Biguanides Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Antidiabetic Biguanides Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Antidiabetic Biguanides Revenue Market Share by Region (2018-2024)
Table 8. Global Antidiabetic Biguanides Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Antidiabetic Biguanides Revenue Market Share by Region (2024-2034)
Table 10. Global Antidiabetic Biguanides Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 11. Global Antidiabetic Biguanides Sales by Region (2018-2024) & (K Pcs)
Table 12. Global Antidiabetic Biguanides Sales Market Share by Region (2018-2024)
Table 13. Global Antidiabetic Biguanides Sales by Region (2024-2034) & (K Pcs)
Table 14. Global Antidiabetic Biguanides Sales Market Share by Region (2024-2034)
Table 15. Global Antidiabetic Biguanides Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 16. Global Antidiabetic Biguanides Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Antidiabetic Biguanides Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Antidiabetic Biguanides Revenue Share by Manufacturers (2018-2024)
Table 19. Global Antidiabetic Biguanides Price by Manufacturers 2018-2024 (USD/Pcs)
Table 20. Global Key Players of Antidiabetic Biguanides, Industry Ranking, 2021 VS 2022
Table 21. Global Antidiabetic Biguanides Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Antidiabetic Biguanides by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antidiabetic Biguanides as of 2022)
Table 23. Global Key Manufacturers of Antidiabetic Biguanides, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Antidiabetic Biguanides, Product Offered and Application
Table 25. Global Key Manufacturers of Antidiabetic Biguanides, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antidiabetic Biguanides Sales Quantity by Type (2018-2024) & (K Pcs)
Table 28. Global Antidiabetic Biguanides Sales Quantity by Type (2024-2034) & (K Pcs)
Table 29. Global Antidiabetic Biguanides Sales Quantity Share by Type (2018-2024)
Table 30. Global Antidiabetic Biguanides Sales Quantity Share by Type (2024-2034)
Table 31. Global Antidiabetic Biguanides Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Antidiabetic Biguanides Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Antidiabetic Biguanides Revenue Share by Type (2018-2024)
Table 34. Global Antidiabetic Biguanides Revenue Share by Type (2024-2034)
Table 35. Antidiabetic Biguanides Price by Type (2018-2024) & (USD/Pcs)
Table 36. Global Antidiabetic Biguanides Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 37. Global Antidiabetic Biguanides Sales Quantity by Application (2018-2024) & (K Pcs)
Table 38. Global Antidiabetic Biguanides Sales Quantity by Application (2024-2034) & (K Pcs)
Table 39. Global Antidiabetic Biguanides Sales Quantity Share by Application (2018-2024)
Table 40. Global Antidiabetic Biguanides Sales Quantity Share by Application (2024-2034)
Table 41. Global Antidiabetic Biguanides Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Antidiabetic Biguanides Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Antidiabetic Biguanides Revenue Share by Application (2018-2024)
Table 44. Global Antidiabetic Biguanides Revenue Share by Application (2024-2034)
Table 45. Antidiabetic Biguanides Price by Application (2018-2024) & (USD/Pcs)
Table 46. Global Antidiabetic Biguanides Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 47. North America Antidiabetic Biguanides Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Antidiabetic Biguanides Sales Quantity by Company (2018-2024) & (K Pcs)
Table 49. North America Antidiabetic Biguanides Sales Quantity by Type (2018-2024) & (K Pcs)
Table 50. North America Antidiabetic Biguanides Sales Quantity by Type (2024-2034) & (K Pcs)
Table 51. North America Antidiabetic Biguanides Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Antidiabetic Biguanides Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Antidiabetic Biguanides Sales Quantity by Application (2018-2024) & (K Pcs)
Table 54. North America Antidiabetic Biguanides Sales Quantity by Application (2024-2034) & (K Pcs)
Table 55. North America Antidiabetic Biguanides Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Antidiabetic Biguanides Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Antidiabetic Biguanides Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Antidiabetic Biguanides Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Antidiabetic Biguanides Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Antidiabetic Biguanides Sales Quantity by Country (2018-2024) & (K Pcs)
Table 61. North America Antidiabetic Biguanides Sales Quantity by Country (2024-2034) & (K Pcs)
Table 62. Europe Antidiabetic Biguanides Sales Quantity by Company (2018-2024) & (K Pcs)
Table 63. Europe Antidiabetic Biguanides Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Antidiabetic Biguanides Sales Quantity by Type (2018-2024) & (K Pcs)
Table 65. Europe Antidiabetic Biguanides Sales Quantity by Type (2024-2034) & (K Pcs)
Table 66. Europe Antidiabetic Biguanides Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Antidiabetic Biguanides Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Antidiabetic Biguanides Sales Quantity by Application (2018-2024) & (K Pcs)
Table 69. Europe Antidiabetic Biguanides Sales Quantity by Application (2024-2034) & (K Pcs)
Table 70. Europe Antidiabetic Biguanides Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Antidiabetic Biguanides Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Antidiabetic Biguanides Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Antidiabetic Biguanides Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Antidiabetic Biguanides Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Antidiabetic Biguanides Sales Quantity by Country (2018-2024) & (K Pcs)
Table 76. Europe Antidiabetic Biguanides Sales Quantity by Country (2024-2034) & (K Pcs)
Table 77. China Antidiabetic Biguanides Sales Quantity by Company (2018-2024) & (K Pcs)
Table 78. China Antidiabetic Biguanides Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Antidiabetic Biguanides Sales Quantity by Type (2018-2024) & (K Pcs)
Table 80. China Antidiabetic Biguanides Sales Quantity by Type (2024-2034) & (K Pcs)
Table 81. China Antidiabetic Biguanides Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Antidiabetic Biguanides Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Antidiabetic Biguanides Sales Quantity by Application (2018-2024) & (K Pcs)
Table 84. China Antidiabetic Biguanides Sales Quantity by Application (2024-2034) & (K Pcs)
Table 85. China Antidiabetic Biguanides Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Antidiabetic Biguanides Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Antidiabetic Biguanides Sales Quantity by Company (2018-2024) & (K Pcs)
Table 88. APAC Antidiabetic Biguanides Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Antidiabetic Biguanides Sales Quantity by Type (2018-2024) & (K Pcs)
Table 90. APAC Antidiabetic Biguanides Sales Quantity by Type (2024-2034) & (K Pcs)
Table 91. APAC Antidiabetic Biguanides Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Antidiabetic Biguanides Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Antidiabetic Biguanides Sales Quantity by Application (2018-2024) & (K Pcs)
Table 94. APAC Antidiabetic Biguanides Sales Quantity by Application (2024-2034) & (K Pcs)
Table 95. APAC Antidiabetic Biguanides Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Antidiabetic Biguanides Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Antidiabetic Biguanides Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Antidiabetic Biguanides Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Antidiabetic Biguanides Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Antidiabetic Biguanides Sales Quantity by Region (2018-2024) & (K Pcs)
Table 101. APAC Antidiabetic Biguanides Sales Quantity by Region (2024-2034) & (K Pcs)
Table 102. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Company (2018-2024) & (K Pcs)
Table 103. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Type (2018-2024) & (K Pcs)
Table 105. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Type (2024-2034) & (K Pcs)
Table 106. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Application (2018-2024) & (K Pcs)
Table 109. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Application (2024-2034) & (K Pcs)
Table 110. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Country (2018-2024) & (K Pcs)
Table 116. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity by Country (2024-2034) & (K Pcs)
Table 117. Pfizer Company Information
Table 118. Pfizer Description and Overview
Table 119. Pfizer Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 120. Pfizer Antidiabetic Biguanides Product and Services
Table 121. Pfizer Antidiabetic Biguanides SWOT Analysis
Table 122. Pfizer Recent Developments
Table 123. AstraZeneca Company Information
Table 124. AstraZeneca Description and Overview
Table 125. AstraZeneca Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 126. AstraZeneca Antidiabetic Biguanides Product and Services
Table 127. AstraZeneca Antidiabetic Biguanides SWOT Analysis
Table 128. AstraZeneca Recent Developments
Table 129. GlaxoSmithKline Company Information
Table 130. GlaxoSmithKline Description and Overview
Table 131. GlaxoSmithKline Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 132. GlaxoSmithKline Antidiabetic Biguanides Product and Services
Table 133. GlaxoSmithKline Antidiabetic Biguanides SWOT Analysis
Table 134. GlaxoSmithKline Recent Developments
Table 135. Merck & Co Company Information
Table 136. Merck & Co Description and Overview
Table 137. Merck & Co Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 138. Merck & Co Antidiabetic Biguanides Product and Services
Table 139. Merck & Co Antidiabetic Biguanides SWOT Analysis
Table 140. Merck & Co Recent Developments
Table 141. Eli Lilly Company Information
Table 142. Eli Lilly Description and Overview
Table 143. Eli Lilly Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 144. Eli Lilly Antidiabetic Biguanides Product and Services
Table 145. Eli Lilly Antidiabetic Biguanides SWOT Analysis
Table 146. Eli Lilly Recent Developments
Table 147. Sanofi Company Information
Table 148. Sanofi Description and Overview
Table 149. Sanofi Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 150. Sanofi Antidiabetic Biguanides Product and Services
Table 151. Sanofi Antidiabetic Biguanides SWOT Analysis
Table 152. Sanofi Recent Developments
Table 153. Takeda Pharmaceuticals Company Information
Table 154. Takeda Pharmaceuticals Description and Overview
Table 155. Takeda Pharmaceuticals Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 156. Takeda Pharmaceuticals Antidiabetic Biguanides Product and Services
Table 157. Takeda Pharmaceuticals Antidiabetic Biguanides SWOT Analysis
Table 158. Takeda Pharmaceuticals Recent Developments
Table 159. Novo Nordisk Company Information
Table 160. Novo Nordisk Description and Overview
Table 161. Novo Nordisk Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 162. Novo Nordisk Antidiabetic Biguanides Product and Services
Table 163. Novo Nordisk Antidiabetic Biguanides SWOT Analysis
Table 164. Novo Nordisk Recent Developments
Table 165. Servier Laboratories Company Information
Table 166. Servier Laboratories Description and Overview
Table 167. Servier Laboratories Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 168. Servier Laboratories Antidiabetic Biguanides Product and Services
Table 169. Servier Laboratories Antidiabetic Biguanides SWOT Analysis
Table 170. Servier Laboratories Recent Developments
Table 171. Boehringer Ingelheim Company Information
Table 172. Boehringer Ingelheim Description and Overview
Table 173. Boehringer Ingelheim Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 174. Boehringer Ingelheim Antidiabetic Biguanides Product and Services
Table 175. Boehringer Ingelheim Antidiabetic Biguanides SWOT Analysis
Table 176. Boehringer Ingelheim Recent Developments
Table 177. Bristol-Myers Squibb Company Information
Table 178. Bristol-Myers Squibb Description and Overview
Table 179. Bristol-Myers Squibb Antidiabetic Biguanides Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 180. Bristol-Myers Squibb Antidiabetic Biguanides Product and Services
Table 181. Bristol-Myers Squibb Recent Developments
Table 182. Key Raw Materials Lists
Table 183. Raw Materials Key Suppliers Lists
Table 184. Antidiabetic Biguanides Distributors List
Table 185. Antidiabetic Biguanides Customers List
Table 186. Antidiabetic Biguanides Market Trends
Table 187. Antidiabetic Biguanides Market Drivers
Table 188. Antidiabetic Biguanides Market Challenges
Table 189. Antidiabetic Biguanides Market Restraints
Table 190. Research Programs/Design for This Report
Table 191. Key Data Information from Secondary Sources
Table 192. Key Data Information from Primary Sources
List of Figures
Figure 1. Antidiabetic Biguanides Product Picture
Figure 2. Global Antidiabetic Biguanides Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Antidiabetic Biguanides Market Share by Type in 2022 & 2034
Figure 4. Metformin IR Product Picture
Figure 5. Metformin SR Product Picture
Figure 6. Global Antidiabetic Biguanides Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Antidiabetic Biguanides Market Share by Application in 2022 & 2034
Figure 8. Hospitals
Figure 9. Clinics
Figure 10. Other
Figure 11. Antidiabetic Biguanides Report Years Considered
Figure 12. Global Antidiabetic Biguanides Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 13. Global Antidiabetic Biguanides Revenue 2018-2034 (US$ Million)
Figure 14. Global Antidiabetic Biguanides Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 15. Global Antidiabetic Biguanides Sales Quantity 2018-2034 (K Pcs)
Figure 16. Global Antidiabetic Biguanides Sales Quantity Market Share by Region (2018-2024)
Figure 17. Global Antidiabetic Biguanides Sales Quantity Market Share by Region (2024-2034)
Figure 18. North America Antidiabetic Biguanides Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 19. North America Antidiabetic Biguanides Revenue YoY (2018-2034) & (US$ Million)
Figure 20. Europe Antidiabetic Biguanides Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. Europe Antidiabetic Biguanides Revenue YoY (2018-2034) & (US$ Million)
Figure 22. China Antidiabetic Biguanides Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. China Antidiabetic Biguanides Revenue YoY (2018-2034) & (US$ Million)
Figure 24. APAC Antidiabetic Biguanides Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. APAC Antidiabetic Biguanides Revenue YoY (2018-2034) & (US$ Million)
Figure 26. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue YoY (2018-2034) & (US$ Million)
Figure 28. The Top 10 and Top 5 Players Market Share by Antidiabetic Biguanides Sales Quantity in 2022
Figure 29. The Top 10 and Top 5 Players Market Share by Antidiabetic Biguanides Revenue in 2022
Figure 30. Antidiabetic Biguanides Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 31. Global Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
Figure 32. Global Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
Figure 33. Global Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
Figure 34. Global Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
Figure 35. North America Antidiabetic Biguanides Revenue Market Share by Company in 2022
Figure 36. North America Antidiabetic Biguanides Sales Quantity Market Share by Company in 2022
Figure 37. North America Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
Figure 38. North America Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
Figure 39. North America Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
Figure 40. North America Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
Figure 41. North America Antidiabetic Biguanides Revenue Share by Country (2018-2034)
Figure 42. North America Antidiabetic Biguanides Sales Quantity Share by Country (2018-2034)
Figure 43. U.S. Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 44. Canada Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 45. Europe Antidiabetic Biguanides Sales Quantity Market Share by Company in 2022
Figure 46. Europe Antidiabetic Biguanides Revenue Market Share by Company in 2022
Figure 47. Europe Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
Figure 48. Europe Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
Figure 49. Europe Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
Figure 50. Europe Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
Figure 51. Europe Antidiabetic Biguanides Revenue Share by Country (2018-2034)
Figure 52. Europe Antidiabetic Biguanides Sales Quantity Share by Country (2018-2034)
Figure 53. Germany Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 54. France Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 55. U.K. Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 56. Italy Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 57. Russia Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 58. China Antidiabetic Biguanides Sales Quantity Market Share by Company in 2022
Figure 59. China Antidiabetic Biguanides Revenue Market Share by Company in 2022
Figure 60. China Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
Figure 61. China Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
Figure 62. China Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
Figure 63. China Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
Figure 64. APAC Antidiabetic Biguanides Sales Quantity Market Share by Company in 2022
Figure 65. APAC Antidiabetic Biguanides Revenue Market Share by Company in 2022
Figure 66. APAC Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
Figure 67. APAC Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
Figure 68. APAC Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
Figure 69. APAC Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
Figure 70. APAC Antidiabetic Biguanides Revenue Share by Region (2018-2034)
Figure 71. APAC Antidiabetic Biguanides Sales Quantity Share by Region (2018-2034)
Figure 72. Japan Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 73. South Korea Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 74. China Taiwan Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 75. Southeast Asia Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 76. India Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 77. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Market Share by Company in 2022
Figure 79. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Market Share by Type (2018-2034)
Figure 81. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Market Share by Application (2018-2034)
Figure 83. Middle East, Africa and Latin America Antidiabetic Biguanides Sales Quantity Share by Country (2018-2034)
Figure 84. Middle East, Africa and Latin America Antidiabetic Biguanides Revenue Share by Country (2018-2034)
Figure 85. Brazil Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 86. Mexico Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 87. Turkey Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 88. Israel Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 89. GCC Countries Antidiabetic Biguanides Revenue (2018-2034) & (US$ Million)
Figure 90. Antidiabetic Biguanides Value Chain
Figure 91. Antidiabetic Biguanides Production Process
Figure 92. Channels of Distribution (Direct Vs Distribution)
Figure 93. Distributors Profiles
Figure 94. Bottom-up and Top-down Approaches for This Report
Figure 95. Data Triangulation
Figure 96. Key Executives Interviewed